Introduction	O

Tea	O
(	O
Camellia	O
sinensis	O
L	O
.	O
)	O
is	O
one	O
of	O
the	O
most	O
widely	O
consumed	O
beverages	O
in	O
the	O
world	O
.	O

(	O
-	O
)	O
-	O
Epigallocatechin	O
-	O
3	O
-	O
O	O
-	O
gallate	O
(	O
EGCG	O
)	O
,	O
which	O
is	O
the	O
major	O
green	O
tea	O
catechin	O
present	O
in	O
the	O
leaves	B-Organ
,	O
is	O
believed	O
to	O
the	O
compound	O
most	O
responsible	O
for	O
the	O
health	O
benefits	O
attributed	O
to	O
tea	O
.	O

EGCG	O
was	O
reported	O
to	O
have	O
antioxidative	O
[	O
1	O
]	O
,	O
[	O
2	O
]	O
,	O
antimutagenic	O
[	O
3	O
]	O
,	O
anti	O
-	O
inflammatory	O
[	O
4	O
]	O
,	O
and	O
anticarcinogenic	O
activities	O
[	O
5	O
]	O
.	O

Although	O
the	O
EGCG	O
concentrations	O
required	O
to	O
elicit	O
the	O
anticancer	B-Cancer
activity	O
have	O
been	O
shown	O
to	O
be	O
more	O
than	O
1	O
microM	O
,	O
the	O
blood	B-Organism_substance
level	O
of	O
EGCG	O
after	O
consuming	O
the	O
equivalent	O
of	O
2	O
-	O
3	O
cups	O
of	O
green	O
tea	O
was	O
0	O
.	O
1	O
-	O
0	O
.	O
6	O
microM	O
and	O
for	O
an	O
equivalent	O
of	O
7	O
-	O
9	O
cups	O
was	O
still	O
lower	O
than	O
1	O
microM	O
[	O
6	O
]	O
,	O
[	O
7	O
]	O
.	O

In	O
a	O
cohort	O
study	O
,	O
daily	O
consumption	O
of	O
ten	O
cups	O
of	O
green	O
tea	O
was	O
required	O
for	O
the	O
cancer	B-Cancer
preventive	O
effect	O
[	O
8	O
]	O
.	O

Moreover	O
,	O
adverse	O
effects	O
of	O
green	O
tea	O
,	O
mainly	O
hepatitis	O
,	O
by	O
consumption	O
of	O
high	O
doses	O
of	O
green	O
tea	O
have	O
been	O
reported	O
[	O
9	O
]	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
enhance	O
the	O
pharmacologic	O
effect	O
of	O
EGCG	O
to	O
obtain	O
the	O
health	O
benefit	O
in	O
reasonable	O
concentration	O
in	O
daily	O
life	O
.	O

We	O
have	O
reported	O
that	O
the	O
cell	B-Cellular_component
-	I-Cellular_component
surface	I-Cellular_component
binding	O
of	O
EGCG	O
and	O
its	O
derivatives	O
is	O
involved	O
in	O
their	O
biological	O
activities	O
[	O
10	O
]	O
-	O
[	O
15	O
]	O
.	O

We	O
have	O
identified	O
the	O
67	O
-	O
kDa	O
laminin	O
receptor	O
(	O
67LR	O
)	O
as	O
a	O
cell	B-Cellular_component
surface	I-Cellular_component
receptor	O
for	O
EGCG	O
that	O
mediates	O
the	O
anticancer	O
activity	O
of	O
EGCG	O
[	O
16	O
]	O
.	O

67LR	O
has	O
been	O
shown	O
to	O
be	O
overexpressed	O
on	O
the	O
cell	B-Cellular_component
surface	I-Cellular_component
of	O
various	O
tumor	B-Cell
cells	I-Cell
[	O
17	O
]	O
.	O

It	O
was	O
postulated	O
that	O
67LR	O
plays	O
a	O
significant	O
role	O
in	O
the	O
tumor	B-Cancer
progression	O
and	O
speculated	O
that	O
studies	O
conducted	O
to	O
define	O
the	O
function	O
of	O
67LR	O
could	O
provide	O
a	O
new	O
approach	O
to	O
cancer	B-Cancer
prevention	O
.	O

Indeed	O
,	O
expression	O
of	O
67	O
LR	O
confers	O
EGCG	O
responsiveness	O
to	O
tumor	B-Cell
cells	I-Cell
in	O
vivo	O
[	O
18	O
]	O
.	O

Vitamin	O
A	O
,	O
also	O
known	O
as	O
retinol	O
,	O
participates	O
in	O
physiological	O
activities	O
related	O
to	O
the	O
immune	B-Anatomical_system
system	I-Anatomical_system
,	O
maintenance	O
of	O
epithelial	B-Tissue
and	O
mucosa	B-Tissue
tissues	I-Tissue
,	O
growth	O
,	O
reproduction	O
,	O
and	O
bone	B-Organ
development	O
.	O

It	O
comes	O
from	O
animal	O
sources	O
,	O
such	O
as	O
eggs	B-Developing_anatomical_structure
,	O
meat	B-Organism_subdivision
,	O
milk	B-Organism_substance
,	O
cheese	O
,	O
cream	O
,	O
liver	B-Organ
,	O
kidney	B-Organ
,	O
cod	O
and	O
halibut	O
fish	O
oil	B-Organism_substance
.	O

In	O
vitro	O
and	O
in	O
animal	O
models	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
vitamin	O
A	O
is	O
involved	O
in	O
the	O
regulation	O
and	O
promotion	O
of	O
growth	O
and	O
differentiation	O
of	O
many	O
cells	B-Cell
[	O
19	O
]	O
.	O

The	O
visual	O
function	O
of	O
vitamin	O
A	O
depends	O
on	O
its	O
natural	O
and	O
synthetic	O
derivatives	O
,	O
retinoids	O
[	O
20	O
]	O
.	O

All	O
-	O
trans	O
-	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
,	O
the	O
active	O
derivative	O
of	O
vitamin	O
A	O
,	O
has	O
been	O
well	O
documented	O
as	O
a	O
growth	O
and	O
differentiation	O
factor	O
in	O
many	O
tissues	B-Tissue
and	O
cells	B-Cell
,	O
and	O
proved	O
to	O
be	O
an	O
effective	O
treatment	O
to	O
many	O
diseases	O
including	O
cancers	B-Cancer
[	O
21	O
]	O
,	O
[	O
22	O
]	O
.	O

Retinoids	O
exert	O
their	O
physiological	O
activities	O
through	O
retinoid	O
receptor	O
nuclear	B-Cellular_component
proteins	O
that	O
belong	O
to	O
the	O
superfamily	O
of	O
steroid	O
/	O
thyroid	O
hormone	O
receptors	O
,	O
of	O
which	O
there	O
are	O
two	O
classes	O
,	O
retinoic	O
acid	O
receptors	O
(	O
RARs	O
)	O
and	O
the	O
retinoic	O
-	O
X	O
receptors	O
(	O
RXRs	O
)	O
,	O
each	O
of	O
which	O
has	O
three	O
subtypes	O
,	O
alpha	O
,	O
beta	O
,	O
and	O
gamma	O
[	O
23	O
]	O
,	O
[	O
24	O
]	O
.	O

The	O
natural	O
ligands	O
for	O
the	O
RARs	O
are	O
ATRA	O
and	O
its	O
stereoisomers	O
9	O
-	O
cis	O
-	O
RA	O
and	O
13	O
-	O
cis	O
-	O
RA	O
,	O
whereas	O
RXRs	O
are	O
activated	O
by	O
9	O
-	O
cis	O
-	O
RA	O
only	O
.	O

ATRA	O
acts	O
through	O
RAR	O
to	O
transcriptionally	O
activate	O
target	O
genes	O
,	O
such	O
as	O
cytochrome	O
P450	O
and	O
CRABI	O
[	O
24	O
]	O
.	O

This	O
study	O
was	O
designed	O
to	O
identify	O
a	O
food	O
component	O
that	O
could	O
be	O
effectively	O
used	O
in	O
combination	O
with	O
EGCG	O
and	O
to	O
investigate	O
the	O
mechanism	O
of	O
action	O
of	O
this	O
combination	O
.	O

By	O
using	O
in	O
vitro	O
and	O
in	O
vivo	O
systems	O
involving	O
a	O
highly	O
metastatic	O
mouse	O
B16	B-Cell
melanoma	I-Cell
cell	I-Cell
line	I-Cell
[	O
25	O
]	O
,	O
we	O
found	O
that	O
ATRA	O
enhances	O
the	O
antitumor	B-Cancer
activity	O
of	O
EGCG	O
by	O
upregulating	O
the	O
67	O
LR	O
expression	O
through	O
RAR	O
.	O

